Keyword: Gland Pharma

Not all Big Pharma's businesses in emerging markets are doing so well, Fosun is buying a smaller stake in Gland, Taiho and Arcus ink cancer option deal.

Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.

Samsung inked a novel drug R&D pact with Takeda, GSK China partnered with Alibaba on HPV vaccination, Gland is revising its M&A deal with Fosun.

Baxter International intends to expand three sterile injectable manufacturing facilities it got in its $625 million deal for Claris Injectables.

It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.

German drugmaker Stada has announced plans to sell itself for €5.32 billion ($5.63 billion) shortly after weighing a $3.7 billion private equity takeout.

London-based private equity firm Permira is buying out Lyophilization Services of New England (LSNE).

China's Shanghai Fosun Pharmaceuticals has reportedly won a bidding war for India's privately held injectable maker Gland Pharma in a rare cross-border deal.

China's Shanghai Fosun has joined the race to buy unlisted Indian injectables maker Gland Pharma, which is valued at around $1.5 billion.

China’s Shanghai Fosun Pharmaceutical has made it official. It wants to expand its sterile manufacturing capabilities and has made a bid for India’s Gland Pharma.